Istvan J Enyedy
Theseus Pharmaceuticals, USA

Istvan J Enyedy
Theseus Pharmaceuticals, USA
In the past 21 years Istvan J Enyedy has been involved in new target evaluation, hit finding, and hit-to-lead optimization projects for several types of target classes using both ligand and structure-based methods. He is coauthor on more than 50 publications and 14 patents/applications. He received his PhD in 1998 at Catholic University of America, Washington DC, and did postdoctoral training in Dr. Shaomeng Wang’s group at Georgetown University Medical Center, Washington DC. Between 2001 and 2021 he worked at Bayer Pharmaceuticals, West Haven CT, Novartis Institutes for Biomedical Research, Biogen, and Black Diamond Therapeutics in Cambridge MA. Since September 2021 he has been at Theseus Pharmaceuticals, in Cambridge MA.
In the past 21 years Istvan J Enyedy has been involved in new target evaluation, hit finding, and hit-to-lead optimization projects for several types of target classes using both ligand and structure-based methods. He is coauthor on more than 50 publications and 14 patents/applications. He received his PhD in 1998 at Catholic University of America, Washington DC, and did postdoctoral training in Dr. Shaomeng Wang’s group at Georgetown University Medical Center, Washington DC. Between 2001 and 2021 he worked at Bayer Pharmaceuticals, West Haven CT, Novartis Institutes for Biomedical Research, Biogen, and Black Diamond Therapeutics in Cambridge MA. Since September 2021 he has been at Theseus Pharmaceuticals, in Cambridge MA.